These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 21912195)

  • 21. Intraoperative assessment of sentinel lymph nodes after neoadjuvant chemotherapy in patients with breast cancer.
    Rubio IT; Aznar F; Lirola J; Peg V; Xercavins J
    Ann Surg Oncol; 2010 Jan; 17(1):235-9. PubMed ID: 19777186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy.
    Hennessy BT; Gonzalez-Angulo AM; Hortobagyi GN; Cristofanilli M; Kau SW; Broglio K; Fornage B; Singletary SE; Sahin A; Buzdar AU; Valero V
    Cancer; 2006 Mar; 106(5):1000-6. PubMed ID: 16444747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast-conserving surgery after neoadjuvant anthracycline-based chemotherapy for large breast tumors.
    Rouzier R; Mathieu MC; Sideris L; Youmsi E; Rajan R; Garbay JR; André F; Marsiglia H; Spielmann M; Delaloge S
    Cancer; 2004 Sep; 101(5):918-25. PubMed ID: 15329898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
    von Minckwitz G; Untch M; Blohmer JU; Costa SD; Eidtmann H; Fasching PA; Gerber B; Eiermann W; Hilfrich J; Huober J; Jackisch C; Kaufmann M; Konecny GE; Denkert C; Nekljudova V; Mehta K; Loibl S
    J Clin Oncol; 2012 May; 30(15):1796-804. PubMed ID: 22508812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is regional lymph node irradiation necessary in stage II to III breast cancer patients with negative pathologic node status after neoadjuvant chemotherapy?
    Daveau C; Stevens D; Brain E; Berges O; Villette S; Moisson P; Gardner M; De la Lande B; Lasry S; Labib A; Le Scodan R
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):337-42. PubMed ID: 20171795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiotherapy can decrease locoregional recurrence and increase survival in mastectomy patients with T1 to T2 breast cancer and one to three positive nodes with negative estrogen receptor and positive lymphovascular invasion status.
    Yang PS; Chen CM; Liu MC; Jian JM; Horng CF; Liu MJ; Yu BL; Lee MY; Chi CW
    Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):516-22. PubMed ID: 19577858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF.
    Wenzel C; Bartsch R; Hussian D; Pluschnig U; Altorjai G; Zielinski CC; Lang A; Haid A; Jakesz R; Gnant M; Steger GG
    Breast Cancer Res Treat; 2007 Jul; 104(1):109-14. PubMed ID: 17061042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.
    Tinari N; Lattanzio R; Natoli C; Cianchetti E; Angelucci D; Ricevuto E; Ficorella C; Marchetti P; Alberti S; Piantelli M; Iacobelli S
    Clin Cancer Res; 2006 Mar; 12(5):1501-6. PubMed ID: 16533774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor reduction rate predicts early recurrence in patients with breast cancer failing to achieve complete response to primary chemotherapy.
    Nagashima T; Sakakibara M; Sangai T; Kazama T; Nakatani Y; Miyazaki M
    Breast Cancer; 2010 Apr; 17(2):125-30. PubMed ID: 19459030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
    Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
    Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results of two randomized trials evaluating adjuvant anthracycline-based chemotherapy in 1146 patients with early breast cancer.
    Arriagada R; Spielmann M; Koscielny S; Le Chevalier T; Delozier T; Rémé-Saumon M; Ducourtieux M; Tursz T; Hill C
    Acta Oncol; 2005; 44(5):458-66. PubMed ID: 16118079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erratum to: Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up.
    Kiluk JV; Ly QP; Santillan AA; Meade T; Ramos D; Reintgen DS; Dessureault S; Davis M; Shamehdi C; Cox CE
    Ann Surg Oncol; 2010 Feb; 17(2):552-7. PubMed ID: 19957043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term outcomes in stage IIIB breast cancer patients who achieved less than a pathological complete response (Ionta MT; Atzori F; Deidda MC; Pusceddu V; Palmeri S; Frau B; Murgia M; Barca M; Minerba L; Massidda B
    Oncologist; 2009 Nov; 14(11):1051-60. PubMed ID: 19897535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical significance of axillary microresiduals after neoadjuvant chemotherapy in breast cancer patients with cytologically proven metastases.
    Sakakibara M; Nagashima T; Kadowaki M; Onai Y; Fujimori T; Yokomizo J; Suzuki H; Fushimi K; Nakatani Y; Miyazaki M
    Ann Surg Oncol; 2009 Sep; 16(9):2470-8. PubMed ID: 19588201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer.
    Hieken TJ; Boughey JC; Jones KN; Shah SS; Glazebrook KN
    Ann Surg Oncol; 2013 Oct; 20(10):3199-204. PubMed ID: 23846781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determining which patients require irradiation of the supraclavicular nodal area after surgery for N1 breast cancer.
    Yu JI; Park W; Huh SJ; Choi DH; Lim YH; Ahn JS; Yang JH; Nam SJ
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1135-41. PubMed ID: 20231065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Success and failure of primary medical, nonoperative management in breast cancer.
    Schmid SM; Modlasiak AA; Myrick ME; Kilic N; Viehl CT; Schötzau A; Güth U
    Ann Surg Oncol; 2011 Aug; 18(8):2166-72. PubMed ID: 21311982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does lymphovascular invasion predict regional nodal failure in breast cancer patients with zero to three positive lymph nodes treated with conserving surgery and radiotherapy? Implications for regional radiation.
    Boutrus R; Abi-Raad R; Niemierko A; Brachtel EF; Rizk L; Kelada A; Taghian AG
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):793-8. PubMed ID: 20171799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.